MA52656A - Procédés de production de cellules exprimant un récepteur recombinant et compositions associées - Google Patents
Procédés de production de cellules exprimant un récepteur recombinant et compositions associéesInfo
- Publication number
- MA52656A MA52656A MA052656A MA52656A MA52656A MA 52656 A MA52656 A MA 52656A MA 052656 A MA052656 A MA 052656A MA 52656 A MA52656 A MA 52656A MA 52656 A MA52656 A MA 52656A
- Authority
- MA
- Morocco
- Prior art keywords
- recombinant
- receiver
- processes
- production
- cells expressing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862653522P | 2018-04-05 | 2018-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52656A true MA52656A (fr) | 2021-02-17 |
Family
ID=66429544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052656A MA52656A (fr) | 2018-04-05 | 2019-04-03 | Procédés de production de cellules exprimant un récepteur recombinant et compositions associées |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210017249A1 (fr) |
EP (1) | EP3775238A1 (fr) |
JP (1) | JP2021520202A (fr) |
KR (1) | KR20210029707A (fr) |
CN (1) | CN112585276A (fr) |
AU (1) | AU2019247200A1 (fr) |
BR (1) | BR112020020245A2 (fr) |
CA (1) | CA3094468A1 (fr) |
IL (1) | IL277702A (fr) |
MA (1) | MA52656A (fr) |
MX (1) | MX2020010459A (fr) |
RU (1) | RU2020135966A (fr) |
SG (1) | SG11202009313VA (fr) |
WO (1) | WO2019195492A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4215543A3 (fr) | 2017-10-03 | 2023-10-11 | Juno Therapeutics, Inc. | Molécules de liaison spécifiques du vph |
EP3773908A1 (fr) | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | Récepteurs de lymphocytes t et cellules modifiées les exprimant |
JP2022531229A (ja) * | 2019-04-30 | 2022-07-06 | メモリアル スローン ケタリング キャンサー センター | 併用治療 |
EP3808765A1 (fr) * | 2019-10-14 | 2021-04-21 | ETH Zurich | Lignée cellulaire pour la découverte et l'ingénierie tcr et leurs procédés d'utilisation |
EP4171616A1 (fr) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Lymphocytes t modifiés exprimant un récepteur recombiné, polynucléotides et procédés associés |
AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
EP4019538A1 (fr) * | 2020-12-22 | 2022-06-29 | Charité - Universitätsmedizin Berlin | Reprogrammation de cellules immunitaires par une intégration ciblée de transgènes de récepteur d'antigène chimérique déficient en zêta |
JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | T細胞療法およびdgk阻害剤の組合せ |
CA3217738A1 (fr) | 2021-05-05 | 2022-05-04 | Immatics Biotechnologies Gmbh | Proteines de liaison a l'antigene se liant de maniere specifique a prame |
WO2023019185A1 (fr) * | 2021-08-10 | 2023-02-16 | Gentibio, Inc. | Compositions et méthodes de modification de treg stables |
WO2023056291A1 (fr) * | 2021-09-28 | 2023-04-06 | Acrigen Biosciences | Compositions et procédés pour modifications d'acide nucléique |
WO2023069790A1 (fr) * | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Procédés de modification de lymphocytes t allogéniques avec un transgène dans un locus de tcr et compositions et procédés associés |
CN113717991B (zh) * | 2021-11-01 | 2022-02-01 | 菁良基因科技(深圳)有限公司 | 一种编辑基因融合的方法 |
WO2023081900A1 (fr) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Lymphocytes t modifiés exprimant un récepteur recombiné de lymphocytes t (tcr) et systèmes et procédés apparentés |
WO2024054944A1 (fr) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combinaison de thérapie cellulaire t et de dosage continu ou intermittent d'inhibiteurs de dgk |
CN116925236A (zh) * | 2023-05-12 | 2023-10-24 | 上海恩凯细胞技术有限公司 | 嵌合转换受体及其应用 |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (fr) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
DE68919715T2 (de) | 1988-12-28 | 1995-04-06 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
DE4123760C2 (de) | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
CA2181548C (fr) | 1994-01-18 | 2009-11-03 | Carlos F. Barbas, Iii | Derives de proteine a doigts zinciques et procedes associes |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
USRE45795E1 (en) | 1994-08-20 | 2015-11-10 | Gendaq, Ltd. | Binding proteins for recognition of DNA |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
WO1996013593A2 (fr) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Recepteurs de lymphocites t monocatenaires solubles |
WO1996018105A1 (fr) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Recepteur de lymphocyte t monocatenaire |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5840306A (en) | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
KR100712256B1 (ko) | 1997-10-02 | 2007-04-27 | 알토 바이오사이언스 코포레이션 | 가용성 단일쇄 t-세포 수용체 단백질 |
DK1066380T3 (da) | 1998-05-19 | 2002-01-28 | Avidex Ltd | Opløselig T-cellereceptor |
WO2000014257A1 (fr) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
ATE309536T1 (de) | 1999-12-06 | 2005-11-15 | Sangamo Biosciences Inc | Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen |
WO2001059450A2 (fr) | 2000-02-08 | 2001-08-16 | Sangamo Biosciences, Inc. | Cellules destinees a la decouverte de medicaments |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
WO2001094944A2 (fr) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
WO2002077029A2 (fr) | 2000-11-07 | 2002-10-03 | City Of Hope | Cellules immunitaires specifiques a cd19 redirigees |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
PT1421115E (pt) | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
CA2474486C (fr) | 2002-01-23 | 2013-05-14 | The University Of Utah Research Foundation | Mutagenese chromosomique ciblee au moyen de nucleases en doigt a zinc |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
JP2005533486A (ja) | 2002-02-20 | 2005-11-10 | ダイアックス、コープ | Mhc−ペプチド複合体結合リガンド |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
EP2806025B1 (fr) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Utilisation de nucléases à doigt de zinc pour stimuler le ciblage de gènes |
US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変t細胞レセプターを発現する細胞 |
CA2579677A1 (fr) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Production de proteines: compositions et methodes |
JP2008514685A (ja) | 2004-10-01 | 2008-05-08 | メディジーン リミテッド | 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するt細胞レセプター |
WO2007139982A2 (fr) | 2006-05-25 | 2007-12-06 | Sangamo Biosciences, Inc. | Procédés et compositions pour l'inactivation de gènes |
WO2007139898A2 (fr) | 2006-05-25 | 2007-12-06 | Sangamo Biosciences, Inc. | Demi-domaines résultant de clivage par génie génétique |
US8361473B2 (en) | 2007-03-29 | 2013-01-29 | Technion Research & Development Foundation Ltd. | Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases |
ES2529166T3 (es) | 2007-03-30 | 2015-02-17 | Memorial Sloan-Kettering Cancer Center | Expresión constitutiva de ligandos coestimuladores en linfocitos T transferidos de forma adoptiva |
CN101679977B (zh) | 2007-04-26 | 2013-05-01 | 桑格摩生物科学股份有限公司 | 向ppp1r12c基因座的靶向整合 |
ES2374863T3 (es) | 2007-12-07 | 2012-02-22 | Miltenyi Biotec Gmbh | Centrífuga para separar una muestra en por lo menos dos componentes. |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
EP2281050B1 (fr) | 2008-04-14 | 2014-04-02 | Sangamo BioSciences, Inc. | Constructions donneuses linéaires pour une intégration ciblée |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
CN102159722B (zh) | 2008-08-22 | 2014-09-03 | 桑格摩生物科学股份有限公司 | 用于靶向单链切割和靶向整合的方法和组合物 |
KR101803737B1 (ko) | 2008-12-04 | 2017-12-01 | 상가모 테라퓨틱스, 인코포레이티드 | 징크 핑거 뉴클레아제를 이용한 랫트의 유전체 편집 |
CA2777053A1 (fr) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Recepteurs de lymphocytes t a chaine unique humains |
PL2496698T3 (pl) | 2009-11-03 | 2019-07-31 | City Of Hope | Skrócony receptor naskórkowego czynnika wzrostu (EGFRt) do selekcji transdukowanych komórek T |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
SG177025A1 (en) | 2010-06-21 | 2012-01-30 | Agency Science Tech & Res | Hepatitis b virus specific antibody and uses thereof |
US9255259B2 (en) | 2010-02-09 | 2016-02-09 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
CA2796600C (fr) | 2010-04-26 | 2019-08-13 | Sangamo Biosciences, Inc. | Edition du genome d'un locus de rosa en utilisant des nucleases a doigt de zinc |
EP2571512B1 (fr) | 2010-05-17 | 2017-08-23 | Sangamo BioSciences, Inc. | Nouvelles protéines se liant à l'adn et leurs utilisations |
AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
CN106220739A (zh) | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
WO2012135854A2 (fr) | 2011-04-01 | 2012-10-04 | Memorial Sloan-Kettering Cancer Center | Anticorps contre des peptides cytosoliques |
EP3320910A1 (fr) | 2011-04-05 | 2018-05-16 | Cellectis | Procédé de génération de nucléases tale compactes et leurs utilisations |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
CN104114233B (zh) | 2011-07-29 | 2021-11-12 | 宾夕法尼亚大学董事会 | 转换共刺激受体 |
CN103917644A (zh) | 2011-09-21 | 2014-07-09 | 桑格摩生物科学股份有限公司 | 调控转基因表达的方法和组合物 |
EP2771457B1 (fr) | 2011-10-27 | 2017-11-22 | Sangamo Therapeutics, Inc. | Procédés et compositions pour la modification du locus hprt |
DK2771357T3 (en) * | 2011-10-28 | 2018-10-29 | Regeneron Pharma | Genetically modified T cell receptor mice |
CN107880101B (zh) | 2011-11-11 | 2021-12-21 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
CA2854819C (fr) | 2011-11-16 | 2022-07-19 | Sangamo Biosciences, Inc. | Proteines de liaison d'adn modifiees et utilisations de celles-ci |
AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (fr) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation |
NZ702108A (en) | 2012-05-03 | 2016-09-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
RU2650819C2 (ru) | 2012-05-07 | 2018-04-17 | Сангамо Терапьютикс, Инк. | Способы и композиции для опосредованной нуклеазой направленной интеграции трансгенов |
MA37681B2 (fr) | 2012-05-25 | 2020-07-29 | Cellectis | Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie |
IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
KR102198058B1 (ko) | 2012-10-02 | 2021-01-06 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
ES2824024T3 (es) | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
US9255250B2 (en) | 2012-12-05 | 2016-02-09 | Sangamo Bioscience, Inc. | Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene |
US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
CA2910489A1 (fr) | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Procedes et compositions pour le traitement d'une maladie genetique |
US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
ES2932429T3 (es) | 2013-07-15 | 2023-01-19 | Us Health | Métodos de preparación de células T anti-antígeno de virus del papiloma humano |
EP3572423B1 (fr) | 2013-07-15 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Récepteurs de lymphocytes t anti-papillomavirus humain 16 e6 |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
US20150098954A1 (en) | 2013-10-08 | 2015-04-09 | Elwha Llc | Compositions and Methods Related to CRISPR Targeting |
ES2782125T3 (es) | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
KR20230152175A (ko) | 2014-04-18 | 2023-11-02 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분 |
CA2945393C (fr) * | 2014-04-24 | 2021-03-23 | Board Of Regents, The University Of Texas System | Application de cellules souches pluripotentes induites pour generer des produits de therapie cellulaire adoptive |
US10301370B2 (en) | 2014-05-02 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor T cells |
MX2016014565A (es) | 2014-05-08 | 2017-05-23 | Sangamo Biosciences Inc | Metodos y composiciones para tratar la enfermedad de huntington. |
DK3149031T3 (da) | 2014-05-29 | 2020-03-16 | Us Health | Anti-human papillomavirus 16 e7 t-cellereceptorer |
US9816074B2 (en) | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
RU2017102769A (ru) | 2014-07-29 | 2018-08-28 | Пфайзер Инк. | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА |
US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
GB201417803D0 (en) * | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
EP3215166B1 (fr) | 2014-10-31 | 2024-04-24 | The Trustees of the University of Pennsylvania | Modification de l'expression génétique dans les cellules car-t et utilisations associées |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
AU2016291778B2 (en) | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
EP4108255A1 (fr) * | 2015-10-05 | 2022-12-28 | Precision Biosciences, Inc. | Cellules génétiquement modifiées comprenant un gène modifié de région constante alpha de récepteur de lymphocytes t humains |
WO2017070429A1 (fr) | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Procédés consistant à éditer des polynucléotides codant pour un récepteur de lymphocytes t |
US20180362975A1 (en) | 2015-12-04 | 2018-12-20 | Novartis Ag | Compositions and methods for immunooncology |
AU2016369490C1 (en) | 2015-12-18 | 2021-12-23 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
GB201604953D0 (en) * | 2016-03-23 | 2016-05-04 | Immunocore Ltd | T cell receptors |
HUE059159T2 (hu) * | 2016-04-08 | 2022-10-28 | Immunocore Ltd | T-sejt-receptorok |
JP2019517788A (ja) | 2016-05-06 | 2019-06-27 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞および同細胞を作製する方法 |
KR102546839B1 (ko) * | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
WO2018073393A2 (fr) * | 2016-10-19 | 2018-04-26 | Cellectis | Cellules allogéniques modifiées par une nucléase d'effecteur tal (talen) appropriées pour une thérapie |
WO2018178378A1 (fr) * | 2017-03-31 | 2018-10-04 | Cellectis Sa | Nouveaux lymphocytes t récepteurs d'antigènes chimériques universels spécifiques pour cd22 |
JP7170666B2 (ja) * | 2017-05-08 | 2022-11-14 | プレシジョン バイオサイエンシズ,インク. | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
EP3621981A2 (fr) * | 2017-05-12 | 2020-03-18 | CRISPR Therapeutics AG | Matériaux et procédés de génie cellulaire et leurs utilisations en immuno-oncologie |
EP3645038A1 (fr) * | 2017-06-30 | 2020-05-06 | Precision Biosciences, Inc. | Lymphocytes t génétiquement modifiés comprenant un intron modifié dans le gène alpha du récepteur des lymphocytes t |
EP4215543A3 (fr) * | 2017-10-03 | 2023-10-11 | Juno Therapeutics, Inc. | Molécules de liaison spécifiques du vph |
-
2019
- 2019-04-03 BR BR112020020245-2A patent/BR112020020245A2/pt unknown
- 2019-04-03 RU RU2020135966A patent/RU2020135966A/ru unknown
- 2019-04-03 WO PCT/US2019/025682 patent/WO2019195492A1/fr active Application Filing
- 2019-04-03 AU AU2019247200A patent/AU2019247200A1/en active Pending
- 2019-04-03 EP EP19722319.1A patent/EP3775238A1/fr active Pending
- 2019-04-03 JP JP2020554180A patent/JP2021520202A/ja active Pending
- 2019-04-03 CA CA3094468A patent/CA3094468A1/fr active Pending
- 2019-04-03 SG SG11202009313VA patent/SG11202009313VA/en unknown
- 2019-04-03 CN CN201980036094.9A patent/CN112585276A/zh active Pending
- 2019-04-03 MA MA052656A patent/MA52656A/fr unknown
- 2019-04-03 US US17/044,221 patent/US20210017249A1/en active Pending
- 2019-04-03 MX MX2020010459A patent/MX2020010459A/es unknown
- 2019-04-03 KR KR1020207031913A patent/KR20210029707A/ko active Search and Examination
-
2020
- 2020-09-30 IL IL277702A patent/IL277702A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2020010459A (es) | 2021-01-20 |
WO2019195492A1 (fr) | 2019-10-10 |
BR112020020245A2 (pt) | 2021-04-06 |
CN112585276A (zh) | 2021-03-30 |
AU2019247200A1 (en) | 2020-10-15 |
EP3775238A1 (fr) | 2021-02-17 |
SG11202009313VA (en) | 2020-10-29 |
JP2021520202A (ja) | 2021-08-19 |
US20210017249A1 (en) | 2021-01-21 |
IL277702A (en) | 2020-11-30 |
CA3094468A1 (fr) | 2019-10-10 |
KR20210029707A (ko) | 2021-03-16 |
AU2019247200A2 (en) | 2022-06-09 |
RU2020135966A (ru) | 2022-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52656A (fr) | Procédés de production de cellules exprimant un récepteur recombinant et compositions associées | |
IL279533A (en) | Creation through artificial intelligence | |
IL287553A (en) | Modified pluripotent cells | |
DK3524699T3 (en) | Building materials comprising digestate | |
MA49979A (fr) | Procédés de production de compositions de cellules génétiquement modifiées et compositions associées | |
MA39746A (fr) | Compositions de sécrétion de polypeptides hétérologues et procédés associés | |
ZA202104358B (en) | Production of lithium chemicals and metallic lithium | |
SG11202112690YA (en) | Methods and cells for production of phytocannabinoids and phytocannabinoid precursors | |
GB201913355D0 (en) | Covalent-organic framework materials and methods of making thereof | |
GB201806072D0 (en) | Methods of manufacture | |
PL3594317T3 (pl) | Frakcjonowanie materiału na bazie biomasy | |
ZA202004864B (en) | Dough composition and process for manufacture | |
IL287106A (en) | Engineered productive cell lines and methods for their preparation and use | |
EP3990247A4 (fr) | Fabrication additive d'un matériau composite thermomécanique amélioré | |
IL283085A (en) | Improved T cell production process | |
MA53557A (fr) | Procédés de culture cellulaire continue | |
MA55562A (fr) | Production de cellules car-t anti-bcma | |
GB201915803D0 (en) | Cell production | |
CA193894S (en) | Building material | |
MA49351A (fr) | Procédés de production et d'utilisation de cellules progénitrices mésenchymateuses embryonnaires | |
GB201817512D0 (en) | Manufacture of biomass based ceramics | |
GB2577737B (en) | Determination of material | |
ZA202107476B (en) | Electrochemical production of polymers | |
CA196230S (en) | Building material | |
GB201910727D0 (en) | Construction material |